[ad_1]
At present, lidocaine, a tissue numbing agent, is rare.
Drug shortages have been generalized for more more than a decade, especially for cheap generic drugs, because of the consolidation of manufacturers, the shutdown of low-profit drug production and the need to solve manufacturing problems. The cost is not just the price of a drug, but the time spent by clinical staff and staff to track supplies, to look for alternatives and to modify protocols. In case of a shortage, hospitals struggle to find other solutions.
The company's goal is to fight drug shortages and higher drug prices by making generic drugs more accessible and affordable. They are launching a non-profit pharmaceutical company to combat rising costs and chronic shortages. The company, called Civica Rx, will be more probably be honest.
The seven groups are Catholic Health Initiatives, HCA Health Care, Intermountain Healthcare, Mayo Clinic, Providence St. Joseph Health, SSM Health and Trinity Health.
Several hospital leaders said that shortages and price spikes on old drugs were handled daily. The intention to start it was announced in January.
The company has identified 14 drugs administered in hospitals to focus first. Harrison refused to name the treatment.
"We think it's wrong," he said.
"We intend to make our prices fully transparent."
In July, the Food and Drug Administration set up a task force to fight drug shortages. A year ago, the Department of Justice and 45 states accused a group of generic drug manufacturers to set prices.
"They are taking very expensive drugs for rare diseases and for which there is no competition, that's fine". And the desire of the company more It is likely that the birth will be done by contracting with existing producers to plan the drugs below its establishment. Finally, he could buy his own manufacturing facilities. This has led manufacturers to buy some generic drugs and to abandon others that do not report as much.
Civica Rx stated that Martin VanTrieste, former quality director at Amgen Inc.
"It only takes one generic company in a market if it acts non-profit to lower the price and make it stable," he said. He says that the production of some generic drugs has become so concentrated that companies hold monopoly power over essential drugs. And since they have already covered their manufacturing and fashion costs, they can offer this vitality to prevent competitors.
"As has been widely reported, some generic drug companies have been criticized for unjustified shortages and arbitrary price increases and artificial problems for patients," said Marc Harrison, CEO of Intermountain Healthcare. Liljenquist argues that long-term stability will be more attractive than the short-term temptation to obtain a market. Early indications point out that he is right.
About 120 health care companies representing about one-third of US hospitals contacted Civica Rx organizers to ask them to participate in the transaction, Harrison said. He acknowledged that manufacturers of unscrupulous generic drugs must be safe.
Civica starts with 14 generic drugs, but the organizers will not say which ones before to be ready to sell.
[ad_2]
Source link
